Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454560 | 0.90 | SRC (0.52) | MEN1KMT2AEPHX2JAK2JAK3 | |
| SCHEMBL3459265 | 0.89 | JAK2 (0.52) | MEN1KMT2AEPHX2JAK2JAK3 | |
| SCHEMBL2877375 | 0.86 | MEN1 (0.71) | MEN1KMT2AEPHX2POLBPKM | |
| SCHEMBL30023094 | 0.80 | KMT2A (0.65) | MEN1KMT2AEPHX2JAK2JAK3 | |
| SCHEMBL14024420 | 0.79 | JAK3 (0.53) | JAK2JAK3CDK2CSF1RTYK2 | |
| SCHEMBL14024541 | 0.77 | KDR (0.57) | SRCPLK4 | |
| SCHEMBL14024626 | 0.76 | KDR (0.49) | JAK2JAK3CSF1RTYK2ULK2 | |
| SCHEMBL13408045 | 0.75 | MEN1 (0.69) | MEN1KMT2AEPHX2KDM4EPOLB | |
| SCHEMBL3459344 | 0.75 | SRC (0.59) | EPHX2SRCKDM4EHTT | |
| SCHEMBL3458627 | 0.74 | EPHX2 (0.64) | EPHX2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | MEN1 1981/4885KMT2A 1032/4885EPHX2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.